Today’s top gainers include the company Novo Nordisk A/S (NYSE:NVO) which is in the industry Drug Manufacturers – Other, gaining -0.50% today. In the last week its performance is -7.33%, and -22.63% for the past quarter. Currently, Novo Nordisk A/S, NVO has a target price of 57, so today’s gain of -0.50% is a significant step towards its target price. The GAP today is therefore -0.53%.
Novo Nordisk A/S (NYSE:NVO), has a market cap of 84812.41, and is based in Denmark. Insider ownership is at 26.40%, and institutional ownership is 10.00%.
At the current price of 41.59, it has a dividend yield of 3.39%, and its target price is 57. This is with a profit margin of 32.70%, and total debt/equity of 0.01. Novo Nordisk A/S (NYSE:NVO) has a P/E of 19.54, as well as a forward P/E of 17.12.
With a current EPS of 2.13, and a forecasted EPS growth for next year at 6.44%,Novo Nordisk A/S (NYSE:NVO) has had a EPS growth for the past five years at 22.40%. For the next five years EPS growth is projected to be 10.90%.
Performance for the year is -22.15%. Since its IPO date on 1/4/1982, the total performance to date is -26.43%.
Volume today for Novo Nordisk A/S (NYSE:NVO), is 5647600, while its average volume is 2645.97. Whilst the total gain today was -0.50%, it did have a day high of -26.86%.
Volatility for this week has been at 1.54%, and 1.40% for the month. The 52-week low for Novo Nordisk A/S, NVO has been -0.41%, while the 52-week-high has reached -27.58%.
Looking at its return of investments, which is 85.00%, and its return on assets is 41.50%. Novo Nordisk A/S (NYSE:NVO) has an operating margin of 43.40%. With a sales growth of 1.50% quarter over quarter. Bearing in mind that Novo Nordisk A/S, NVO is in the sector Healthcare, its long-term debt/equity is 0, and has a current ratio of 1.3 and 0.9 for quick ratio.
So what is the value of Novo Nordisk A/S? Well its PEG is 1.79, and the P/S is 5.1, along with a P/B of 16.44. Meanwhile it has a p/cash of 37.